Abstract
Objective-To study the effects of sulphasalazine (SASP) on the systemic and mucosal humoral immune systems in patients with rheumatoid arthritis (RA). Methods-Serum concentrations of interleukin 6 (IL-6), class and subclass specific IgG, IgA and IgM, IgA and IgG antigliadin antibodies and rheumatoid factors (RF) of IgG, IgA (including IgAl and IgA2 subclasses) and IgM isotypes were measured before and 16 weeks after sulphasalazine (SASP) therapy in 15 female and three male patients with RA. Amounts of immunoglobulins in saliva and jejunal fluid were measured as estimates of mucosal humoral immunity. Results-Serum concentrations of IgA and IgG decreased significantly during SASP therapy and correlated with reduced concentrations of IL-6. In addition, levels of circulating IgA RF, IgA anti-gliadin antibodies and IgM RF decreased significantly after the treatment. In contrast, immunoglobulin levels in saliva and jejunal fluid were unaltered. Conclusion-SASP exerts powerful but selective inhibitory effects on systemic immunoglobulin production, whereas no effects on mucosal immunoglobulin production were observed. The decreased systemic B celi activity may be mediated by downregulation ofthe production ofIL-6, a cytokine with Ig switching properties.
(Ann Rheum Dis 1995; 54: 256-262) Sulphasalazine (SASP) has been shown to be an effective agent for the treatment of rheumatoid arthritis (RA), although the mode of action by which it reduces disease activity is unclear. SASP has been reported to reduce neutrophil function' 2 in addition to possessing immunomodulatory effects,3-6 but may also induce a state of humoral immunodeficiency.79
Because SASP also displays potent beneficial properties in inflammatory bowel disease, interest has been focused on the possibility that the effect of SASP on RA may be mediated by modulation of intestinal immunity.10 11 The rationale for this hypothesis includes the proposal of an enteric cause of RA,'2 findings that certain dietary antigens exacerbate symptoms in RA,'3 and more recent observations that some patients with RA display ileocaecal inflammation. ' 4 SASP has been shown to decrease intestinal inflammation in RA patients. 5 The mucosal immune system is considered to be the major immunoglobulin forming organ in the human body. '6 The intestinal immunocytes produce mainly secretory IgA (sIgA), '7 and are frequently triggered by orally delivered antigens. '8 '9 Occurrence of IgA rheumatoid factor (RF) has been linked to RA with systemic manifestations, an erosive disease course, or a severe disease outcome.20 -23 IgA RF has been shown to be produced in the mucosal compartments,24 25 and is suggested to be a marker of inflammation in or near mucosal membranes.26 Activation of the mucosal immune system should therefore be considered in the pathogenesis of RA. To study in vivo if the administration of SASP affected humoral immunity in the gastrointestinal tract and peripheral blood in RA patients, we prospectively analysed the concentrations of major classes and subclasses of immunoglobulins in serum, saliva, and jejunal fluid, in addition to the serum levels and isotypic distribution of RF and anti-gliadin antibodies before and after 16 (OD) values were converted to g/l using calibration curves based on the OD obtained from serial dilutions of the respective highly purified IgA myeloma proteins. Calibration curves were constructed using a computer program based on the weighted logit-log model.30 DETERMINATION OF SERUM IL-6 LEVELS Serum levels of IL-6 were determined by a bioassay as previously described.3' Briefly, we used B9 subclone32 originating from cell line B 13-29, which is dependent on IL-6 for growth. B9 cells were harvested from tissue culture flasks, seeded into microtitre plates (Nunc, Roskilde, Denmark) at a concentration of 5000 cells per well, and cultured in Isocove's medium supplemented with 5 x 10-5 molI 2-mercaptoethanol, 5% FCS, and 50 pug/ml gentamycin. Heat inactivated serially diluted serum samples and recombinant human IL-6 standard (Genzyme, Cambridge, MA, USA) were added to the wells. 3H-Thymidine was added after 68 hours of culturing, and the cells were harvested four hours later. All samples were run in triplicate. The sensitivity limit for this assay is below 1 pg/ml. B9 cells were previously shown not to react with several recombinant cytokines, including IL-iot and P, IL-2, IL-3, IL-5, granulocyte macrophage colony stimulating factor, tumour necrosis factor cx and interferon gamma. There was only weak reactivity with IL-4.33 SALIVA AND JEJUNAL ASPIRATE Unstimulated whole saliva was collected in the morning after overnight fasting by direct expectoration into a sterile plastic container and was kept at -70°C until required for analysis. In order to obtain jejunal aspirate with a minimum of microbial contamination from the stomach and oral cavity, a special closed tube system (RHP-1 2.0, William Cook Europe AB, Bjaeverskov, Denmark) was used, as described earlier. 34 The tube system was attached to the biopsy collecting device during intubation and clearly visualised fluoroscopically. Aspirate was collected from the proximal part of jejunum immediately before biopsy sampling and thereafter kept in plastic tubes at -70°C until analysis.
DETERMINATION OF IMMUNOGLOBULINS IN SALIVA AND JEJUNAL ASPIRATE
The saliva and jejunal samples were thawed and centrifuged for 15 minutes at 10 000 g at 4°C and the supernatant assayed by ELISA. 35 Each sample of saliva and jejunal fluid was tested in duplicate at three fivefold dilution steps. All saliva and jejunal fluid samples were diluted in PBS containing 0-050/o Tween 20 (Polysorbatum 20, Apoteksbolaget, Sweden) (PBS-Tween). Polystyrene microtitre plates (M 129B, Dynatech) were coated overnight with anti-immunoglobulins at room temperature and stored at 4°C until used. Each well was coated with 100 pl of rabbit immunoglobulins directed toward human IgM (2-55 ,ug/ml) (pL specific, Dakopatts), IgG (2 85 ,ug/ml) (,y specific, Dakopatts), IgA (1) (2) (3) (4) (5) p.g/ml) (aC specific, Dakopatts), or secretory component (0-85 ,ug/ml) (Dakopatts) in 0-1 mol/l carbonate-bicarbonate buffer (pH 9 6). The microtitre plates coated with antibodies against secretory component were blocked with 100 pI bovine serum albumin (Sigma), 5 mg/ml, for four hours at room temperature. Saliva and jejunal samples, diluted 1:1250, 1:6250, 1:31250 for sIgA and IgA, and 1:250, 1:1250, 1:6250 for IgG and IgM, were added to the microtitre plate wells in a volume of 100 pAl and incubated overnight at room temperature.
Between the various incubation steps, the wells were rinsed five times with saline containing 0 05% Tween 20 (saline-Tween). Alkaline phosphatase (ALP) conjugated immunoglobulin fractions (100 plI) of monospecific rabbit antisera to human IgM, IgG, and IgA (Dakopatts) diluted 1: 1000 in salineTween were added and incubated for three hours at room temperature. After the final wash, disodium p-nitrophenyl phosphatase, 1 mg/ml (Sigma) in 10% diethanolamine buffer was added and the absorbance measured at 405 nm at 10 minute intervals.
Colostrum was collected from five individuals and pooled. The purification of IgA from colostrum was performed by removing IgG and IgM by affinity chromatography using cyanogen bromide (CNBr)-activated Sepharose 4B (Pharmacia, Uppsala, Sweden Briefly, the inner surfaces of polystyrene Petri dishes were coated with 25 ptg/ml of heat aggregated rabbit IgG. Melted agar was then poured into each dish. Wells 3 mm in diameter were punched in the gel and filled with the serum samples. After incubation at room temperature for 66 hours in a humid atmosphere, the agar was removed. The respective affinity purified, biotinylated F(ab')2 fragments of anti-human IgG or IgM (Dakopatts), diluted 1: 1000 in PBS-Tween were then poured into the dishes. After a two hour incubation, the dishes were rinsed, reincubated for a further one hour with 1 pg/ml horseradish peroxidase labelled avidin (Sigma) and rinsed; finally, melted 1% agar, containing 0.05% paraphenylenediamine and 0-01% H202 was poured into each dish. Positive reactions were recognised as gradually developing, brownish, circular areas. All the plates were photographed after 15 minutes and the diameters of the coloured areas were measured with a ruler to the nearest mm. Reference levels for RF isotypes have been established in a previous study. 20 To assess RF levels of IgA subclasses, the DIG-ELISA assay was used, with 5 p.g/ml monoclonal anti-IgAl or anti-IgA2 (Nordic) antibodies instead of class specific reagents. After two hours incubation the dishes were rinsed and reincubated with F(ab')2 fragments of affinity purified and biotinylated rabbit antimouse IgG (Dakopatts) diluted 1 Table 3 shows serum levels of RF isotypes. After SASP therapy, highly significant reductions in IgA RF, IgAl RF, and IgM RF were noted, but only minor reductions in IgA2 RF and IgG RF.
Discussion
In the present study, SASP treatment of RA patients did not affect the amounts of IgA, sIgA, IgG or IgM produced in mucosal compartments. In contrast, the reduction in serum IgA was highly significant, as was that in serum IgG. In addition, serum IgA RF, IgM RF and IgA class anti-gliadin antibody levels decreased significantly as a consequence of SASP administration.
IgA, which is the major immunoglobulin in secretory glands and the gastrointestinal tract, '7 Serum IgA, like IgG and IgM, is mainly derived from the bone marrow, with smaller contributions from the spleen and peripheral lymph nodes,46 47 and its synthesis is largely independent of sIgA concentrations. This fact, in conjunction with the observed simultaneous and significantly intercorrelated changes in serum IgA and serum IgG (but not sIgA in saliva and jejunal fluid) induced by SASP, strongly suggests that SASP affects the systemic lymphoid compartment, and hardly reflects immunomodulatory effects at the intestinal level.
The decrease in IL-6 in serum after SASP therapy was correlated with the decrease in IgA and IgG concentrations in serum. Besides inducing acute phase proteins, IL-6 is a potent B cell differentiation factor48 and is closely involved in the regulation of IgA and IgG production. This raises the possibility that the decreased serum immunoglobulin concentrations observed during SASP treatment may depend on SASP inhibiting IL-6 production in the synovial membrane and other loci. The proposed downregulation of B cells in the systemic lymphoid compartment may also be a direct effect of the drug on B cells or regulatory T cells, or both, as shown previously in vitro.3 4 69 70 IgA RF is predominantly polymeric7' and has therefore been considered to originate from mucosal tissues. However, more recent studies have shown that this RF isotype is also present and may be produced in nonmucosal compartments.25 70 71 Furthermore, evidence for local production of both IgAl RF and IgA2 RF subclasses in mucosal (saliva) and in non-mucosal (synovial fluid) compartments has been put forward, and a predominance of IgA2 RF production in salivary glands compared with synovial fluid was observed. 25 Reduction of RF has been demonstrated after treatment with SASP and other antirheumatic agents, for example D-penicillamine, gold, and methotrexate.3 53 55 [72] [73] [74] [75] [76] Because the changes in IgA RF and IgM RF did not correlate with the respective changes in serum immunoglobulin concentrations in the SASP treated patients (data not shown), the reductions in RF are not considered to be related to the changes in the overall production of immunoglobulins. Rather, it seems plausible that SASP directly inhibits RF production, an influence that is selective for IgA RF and IgM RF-committed B cells, as synthesis of IgG RF was not affected. A similar differential effect of antirheumatic drugs on the various RF classes has also been demonstrated for penicillamine73 and gold. 74 The observed significant reduction in IgAl RF as opposed to IgA2 RF induced by SASP treatment may further indicate a differential effect of SASP on systemic and mucosal immunity.
In summary, the results from this study indicate that SASP exerts powerful inhibitory effects on systemic IgA and IgG production, but is devoid of similar effects in mucosal tissues, judged by its lack of effect on immunoglobulin production in saliva and jejunal fluid. The effect of SASP on circulating levels of IgA anti-gliadin antibodies mirrors that on systemic immunity and favours the previously presented concept that these antibodies are not of mucosal origin.77 78 Finally, SASP seems selectively to inhibit production of IgA and IgM RF independently of its effect on corresponding serum immunoglobulin concentrations. 
